Clinical trials
Observational Astigmatism trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
84 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 7 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 6 |
| 2022 | 7 |
| 2023 | 6 |
| 2024 | 9 |
| 2025 | 7 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 47 |
| Unknown status | 15 |
| Recruiting | 8 |
| Terminated | 4 |
| Withdrawn | 3 |
| Active, not recruiting | 3 |
| Enrolling by invitation | 2 |
| Not yet recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alcon Research | 8 |
| Bausch & Lomb Incorporated | 3 |
| Tianjin Eye Hospital | 3 |
| Wenzhou Medical University | 3 |
| Assiut University | 2 |
| Edward E. Manche | 2 |
| Food and Drug Administration (FDA) | 2 |
| Mann Eye Institute | 2 |
| OFTALVIST (Oftalmología Vistahermosa S.L) | 2 |
| Prim. Prof. Dr. Oliver Findl, MBA | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Astigmatism | 84 |
| Myopia | 27 |
| Cataract | 22 |
| Hyperopia | 15 |
| Refractive Errors | 10 |
| Corneal Diseases | 5 |
| Keratoconus | 4 |
| Presbyopia | 4 |
| Dilatation, Pathologic | 3 |
| Glaucoma | 3 |
Trials
Showing 76 to 84 of 84. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.